Home  /  Resource Library  /  SURVIVAL AMONG PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH SINGLE AGENT ORAL SELINEXOR IN THE SADAL STUDY

SURVIVAL AMONG PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) TREATED WITH SINGLE AGENT ORAL SELINEXOR IN THE SADAL STUDY

EHA 2020: Results of a phase II study investigating selinexor for the treatment of relapsed DLBCL.